Jump to content
Powered by
  • BIOPRO BW
  • Healthcare industry
  • Bioeconomy

Healthcare industry

Main navigation

  • Start page
  • Healthcare industry BW

    Healthcare industry BW

    Close
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles

    Articles

    Close
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events

    Events

    Close
  • Databases

    Databases

    Close
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services

    BIOPRO services

    Close
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • de
  • en
Show menu

You are here:

  1. Home
  2. Search
Show:Results per page
  • 25Show results
  • 50Show results
  • 75Show results

Search Results

  • Lab-on-a-chip - 11/11/2020 Bild_3.jpg

    Microfluidic platform for the best possible cancer therapy

    Every tumour and every patient is different, and there are individual reactions to drugs as well as the problem of resistance. Patient-specific cancer treatments require innovative and cost-effective approaches. The TheraMe! consortium has developed a novel instrument: a combination of microfluidic experiments and mathematical modelling for use in cancer precision medicine to prevent incorrect therapy options.

    https://www.gesundheitsindustrie-bw.de/en/article/news/microfluidic-platform-best-possible-cancer-therapy
  • Press release - 15/10/2020

    Common Vulnerabilities of Coronaviruses

    International study in which Freiburg scientists are participating maps molecular targets for possible therapy for MERS, SARS-CoV1, and SARS-CoV2.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/common-vulnerabilities-coronaviruses
  • Press release - 08/04/2020

    New Alliance in the Fight Against Coronavirus and COVID-19

    Scientists from Heidelberg and Mannheim launch research and development task force

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/allianz-im-kampf-gegen-coronavirus-und-covid-19
  • Article - 09/10/2019 Der Kopf eines Wissenschaftlers vor einem Computerbildschirm mit Molekülmodell.

    Epigenomics from the Cyber Valley

    Cyber Valley Stuttgart-Tübingen is a European hotspot for artificial intelligence and home to many renowned experts and scientists. They are now joined by Gabriele Schweikert, who heads up the Computational Epigenomics research group in the Cyber Valley’s Division of Computational Biology. Schweikert is interested in exploring epigenetic mechanisms using machine learning methods.

    https://www.gesundheitsindustrie-bw.de/en/article/news/epigenomik-aus-dem-cyber-valley
  • Article - 30/01/2019 Photo of Sven Benson.

    candidum – computer-assisted enzyme design

    Industry has been using enzymes for over a hundred years. While it initially had to content itself with natural enzymes, it is now increasingly possible to design tailor-made biocatalysts with specific properties. The start-up company candidum GmbH from Stuttgart promises to achieve this faster than ever before - mostly thanks to accelerated virtual screening.

    https://www.gesundheitsindustrie-bw.de/en/article/news/candidum-computer-assisted-enzyme-design
  • Company profile - 09/01/2019 Schematic showing the molecular structure of calicheadmicin at the target of the enzyme, i.e. DNA, that is also shown schematically. Figure: HQS Quantum Simulations

    HQS Quantum Simulations for industrial quantum mechanics applications

    The door to the quantum world is opening wider and wider. Behind it is a whole new view of materials and molecules. Quantum mechanics applications not only benefit science, they also offer huge economic potential. The Karlsruhe start-up HQS Quantum Simulations is playing a pioneering role in quantum simulations for the chemical and pharmaceutical industries.

    https://www.gesundheitsindustrie-bw.de/en/article/news/hqs-quantum-simulations-for-industrial-quantum-mechanics-applications
  • Press release - 29/11/2018

    Hattrick in Freiburg

    Three researchers at the MPI for Immunobiology and Epigenetics receive millions in funding from the European Research Council. Dominic Grün, Nicola Iovino and Ritwick Sawarkar from the Max Planck Institute of Immunobiology and Epigenetics in Freiburg will each be awareded one of the prestigious Consolidator Grants of the European Research Council. This means that 6 million euros in funding will go to fundamental research in Freiburg over the next…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/hattrick-in-freiburg
  • Press release - 27/09/2018

    Three new Clusters of Excellence for Tübingen

    University takes next hurdle in the German government’s Excellence Strategy funding program. The University of Tübingen is to have three new Clusters of Excellence.As part of the German government’s Excellence Strategy funding forhigher education research, Tübingen will host new outstanding research networks starting in January 2019. Representatives of Germany’s higher education policymakers announced the decision in Bonn on Thursday.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/three-new-clusters-of-excellence-for-tuebingen
  • Dossier - 28/08/2018 Woman wearing a white lab coat in a laboratory looking at a tube she is holding in her hand.

    With molecular diagnostics to biomarker-based personalised therapy

    Diagnosing suitable biomarkers is a prerequisite for tailoring personalised therapies to patient heterogeneity. Genetic tests and genome sequencing play a key role in these diagnoses. Up until now, personalised therapy has achieved the greatest success in the field of oncology. However, personalised treatments are also gaining in importance for treating other diseases.

    https://www.gesundheitsindustrie-bw.de/en/article/dossier/with-molecular-diagnostics-to-biomarker-based-personalised-therapy
  • Big Data - 26/03/2018 Schematic showing how data of a patient from different sources such as imaging and molecular diagnostics along with expert comments are combined and used for making a decision.

    Eliciting reliable information from big data with classifiers and multimodal data fusion

    Prof. Hans A. Kestler knows a great deal about large amounts of data. He heads up the Institute of Medical Systems Biology at the University of Ulm and is constantly inundated with cooperation enquiries from clinicians. On behalf of BIOPRO, Walter Pytlik asked him whether the conditions for using big data more in biomedical research are already largely present.

    https://www.gesundheitsindustrie-bw.de/en/article/news/eliciting-reliable-information-from-big-data-with-classifiers-and-multimodal-data-fusion
  • Big Data - 13/03/2018 Viegas-User-Activity-on-Wikipedia.png

    “More data does not automatically imply more knowledge“

    In Germany, one of the big names in evidence-based medicine is Prof. Dr. rer. nat. Gerd Antes, co-director of Cochrane Germany. In the following interview, Antes talks about the hype surrounding big data, warns against false promises and reminds us about what is taken for granted.

    https://www.gesundheitsindustrie-bw.de/en/article/news/more-data-does-not-automatically-imply-more-knowledge
  • Big Data - 14/12/2017 Schematic showing the potential explanatory power of chance finds.

    Looking at the whole genome raises new questions

    Research laboratories around the world have long focused on studying the whole human genome. It is hoped that knowing the whole human genome will improve diagnostics and enable more specific therapies. Although genome analysis has not yet reached routine clinical application, whole genome sequencing has already raised many ethical and legal issues - for researchers, physicians and patients.

    https://www.gesundheitsindustrie-bw.de/en/article/news/looking-at-the-whole-genome-raises-new-questions
  • Article - 07/12/2017 Screenshot showing the separation of biomolecules. Coloured lines or peaks represent different components: antibody (pink), contaminated with lysozyme (dark blue) and myoglobin (light blue).

    GoSilico: a formula for the industrial purification of biomolecules

    “Stop experimenting – GoSilico” is the motto of a young start-up company from Karlsruhe. The founding team of GoSilico GmbH is causing a furore with a simulation software that would make many laboratory experiments obsolete. The chromatographic separation of biomolecules from organisms, samples and cell cultures can be reliably simulated after just a few starter experiments. This saves time, work, material and costs in pharmaceutical development.

    https://www.gesundheitsindustrie-bw.de/en/article/news/gosilico-a-formula-for-the-industrial-purification-of-biomolecules
  • Press release - 02/06/2017

    GATC to be part of Eurofins Group

    GATC, one of the leading sequencing provider will be a part of the Eurofins Group as of July 2017 to create the leading company in the worldwide sequencing market.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/gatc-wird-ein-teil-der-eurofins-gruppe
  • Personalised Medicine - 04/05/2017 BigData-Onkologie-doehner_hartmut_eberhardt_kiz.jpg

    Big data make therapy work better

    An international team of researchers has shown for acute myeloid leukaemia (AML) that cancer therapy can be personalised using big data. The authors of the study “believe this paper is a step towards validation of genetic techniques as a route to personalised medicine”.

    https://www.gesundheitsindustrie-bw.de/en/article/news/mit-big-data-genauer-therapieren
  • Article - 20/03/2017 The photo shows keys of a computer keyboard in front of clouds.

    Expansion of the de.NBI, the German Network for Bioinformatics Infrastructure

    The German Network for Bioinformatics Infrastructure, de.NBI for short, is a successful model for infrastructures in the life sciences and biomedicine that is currently being expanded. The network, which was established in 2015, will benefit from more hardware, more staff, more projects and its own cloud. It has also joined the European ELIXIR network.

    https://www.gesundheitsindustrie-bw.de/en/article/news/expansion-of-the-denbi-the-german-network-for-bioinformatics-infrastructure
  • Article - 21/12/2016 Signatope GmbH’s founding team (from left to right) Prof. Dr. Hugo Hämmerle, Dr. Oliver Pötz, Dr. Hannes Planatscher, Dr. Octavian Schatz and Dr. Thomas Joos.

    For all types of tests: Signatope’s biomarker assays

    Signatope is a new biotech company that has been offering innovative biomarker assays for application in drug discovery since August 2016. The company’s assays can be used in all phases of drug development to detect potential adverse drug effects on the kidneys, liver and other organs in any species whatsoever using minute amounts of sample.

    https://www.gesundheitsindustrie-bw.de/en/article/news/for-all-types-of-tests-signatopes-biomarker-assays
  • Article - 26/10/2016 genewerk-cmyk.jpg

    GeneWerk: precision analyses for humans

    Gene therapy approaches are increasingly being used for treating life-threatening diseases in humans. GeneWerk GmbH, a spin-off of the DKFZ and the NCT in Heidelberg, offers customised, high-resolution molecular and bioinformatic analyses that ensure the efficacy and safety of gene therapy and immunotherapy studies.

    https://www.gesundheitsindustrie-bw.de/en/article/news/genewerk-precision-analyses-for-humans
  • Article - 20/09/2016 Prof. Dr. Anita Marchfelder, spokesperson and coordinator of the DFG research group FOR1680.

    CRISPR-Cas has more surprises in store

    Since 2012, a DFG-funded research group called FOR1680 has been studying CRISPR-Cas, an immune system that unicellular bacteria and arachaea use to protect themselves against attacks from viruses and plasmids. Prof. Dr. Anita Marchfelder, a molecular biologist at Ulm University and coordinator of the FOR1680 research group, and many other researchers were surprised to find that prokaryotes incorporate the genetic material of enemies as a kind of…

    https://www.gesundheitsindustrie-bw.de/en/article/news/crispr-cas-has-more-surprises-in-store
  • Company profile - 05/07/2016 Logo_final.jpg

    HS-Analysis GmbH – using digital histology to develop new drugs

    The idea of analysing tissue samples automatically sounds more of a pipe dream than anything else. However, it already happens. HS-Analysis GmbH's ability to interpret tissue samples automatically is driving new drug development a decisive step forward.

    https://www.gesundheitsindustrie-bw.de/en/article/news/hs-analysis-gmbh-using-digital-histology-to-develop-new-drugs
  • Researcher profile - 13/06/2016 3D matrix showing the relationships between Pseudomonas aeruginosa strains. Each strain is represented by a dot. The closer the strains are related to each other, the smaller the distance between them. The matrix shows four groups of strains in four different colours.

    Matthias Willmann wants to get the big picture – tracking down infectious agents

    While fighting and curing bacterial infections in sick patients is one part of the picture, epidemiological investigation of the spread of pathogens is another. Dr. Matthias Willmann also assesses the impact of these factors on the healthcare system as a whole and draws conclusions that might boost early detection of pathogens and prevention of infections.

    https://www.gesundheitsindustrie-bw.de/en/article/news/matthias-willmann-wants-to-get-the-big-picture-tracking-down-infectious-agents
  • Article - 30/05/2016 The photo shows a next-generation sequencer consisting of a sequencing unit and a desktop computer.

    The unknown dark spot of the microcosm

    The world of microorganisms is still largely unknown. Researchers such as Kai Sohn from the Fraunhofer IGB in Stuttgart are working on decoding, analysing and gradually gaining a better understanding of the microbial genome. In their search for new enzymes and other biomolecules, both biotechnologists and pharmacologists are interested in micoorganisms, and physicians are hoping that detailed insights into the microbial genome will lead to the…

    https://www.gesundheitsindustrie-bw.de/en/article/news/the-unknown-dark-spot-of-the-microcosm
  • Article - 12/05/2016 Grey, three-dimensional molecule model surrounded by red RNA sequences.

    Novel method for predicting the spatial structure of biomolecules

    Biomolecules can only fulfil their functions in the cell when they fold into a characteristic native three-dimensional structure. Knowing this structure is not only of paramount importance for basic research, but also for medicine and pharmacology. Scientists from the Karlsruhe Institute of Technology (KIT) have therefore developed a simple method to predict the three-dimensional structure of biomolecules from the analysis of readily available…

    https://www.gesundheitsindustrie-bw.de/en/article/news/novel-method-for-predicting-the-spatial-structure-of-biomolecules
  • Article - 15/02/2016 Rolf Backofen sitting in front of his PC.

    Bacteria – a treasure box for genetic engineers

    Bacteria have developed a versatile defence system to protect themselves against viral infections. One of these defence tools, known as CRISPR/Cas9 system, is currently hogging the headlines as it promises to revolutionise the way genetic material can be modified. Prof. Rolf Backofen from the Institute of Bioinformatics at the University of Freiburg has managed to classify the defence system of all bacterial species sequenced to date. This will…

    https://www.gesundheitsindustrie-bw.de/en/article/news/bacteria-a-treasure-box-for-genetic-engineers
  • Digitalisation - 10/12/2015 The Connector is about the size of a palm of a hand.

    cubuslab helps laboratories to enter the digital era

    cubuslab, a start-up company that was spun off from the Karlsruhe Institute of Technology in March 2015, has developed a technology to connect different types of laboratory equipment, from precision balances to analytical instruments. The technology is aimed at automating workflows and connecting and storing data in an electronic laboratory notebook.

    https://www.gesundheitsindustrie-bw.de/en/article/news/cubuslab-helps-laboratories-to-enter-the-digital-era

Page 1 / 5

sb_search.block.search_result.other.pages

  • 1
  • 2
  • 3
  • 4
  • 5
  • eine Seite zurück
  • Extend search to all portals
  • Search the Healthcare industry database
  • Search the Research institutions
Search terms
Portal
Information type
  • Type
    Event date
    From
    To
  • Type
  • Publication date
    Topics
    Topics
  • Publication date
Reset

Footer navigation

  • Healthcare industry BW
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events
  • Databases
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • Project pages
    • Telemedicine BW
    • MDR & IVDR
  • Portals
    • BIOPRO BW
    • Healthcare industry
    • Bioeconomy
  • To top

stay informed

Subscribe to newsletter

Social Media

  • Xing
  • Twitter
  • LinkedIn
  • Rss
  • Privacy statement
  • Legal notice
  • Sitemap
  • Contact
© 2021
Website address: https://www.gesundheitsindustrie-bw.de/en/search